Beyond the Scale and the Cuff: A New Blueprint for Managing Blood Pressure and Weight

Part I: The Vicious Cycle: My Battle with the Whack-a-Mole Approach

Introduction: The Patient Who Taught Me Everything

For years, I practiced medicine the way I was trained: identify the problem, find the right tool, and fix it. High blood pressure? Prescribe an antihypertensive. High cholesterol? A statin. It was a logical, linear process. Then I met David, and David taught me that the human body is anything but linear.

David was in his early 50s, a dedicated patient who took his health seriously. When his blood pressure crept into the hypertensive range, he was ready to do whatever it took. We started him on a standard, highly effective medication, and within weeks, his numbers were perfect. On paper, it was a resounding success. But over the next year, something else happened. Despite his diligent efforts with diet and exercise—efforts I believed and trusted—the number on his scale climbed steadily. Fifteen pounds. His frustration was palpable. “Doc, I’m doing everything right,” he’d say, his voice a mix of confusion and despair. “I’m eating salads, I’m walking every day. Why is this happening?”

I ran the usual tests, offered the standard advice about calorie counting, and quietly wondered if he was being entirely truthful about his lifestyle. But the look in his eyes told a different story. He felt betrayed by his own body, and worse, by the very treatment meant to protect him. His story became a turning point for me. I had solved one problem, his hypertension, only to watch another—weight gain and worsening metabolic markers—emerge in its place.¹ We were playing a frustrating game of clinical whack-a-mole, and my patient was losing. This experience forced me to ask a difficult question: Was I truly helping my patients achieve health, or was I just trading one disease for another?

The Conventional Wisdom Trap: Why Standard Care Can Fail

David’s predicament was a classic example of a fundamental flaw in the conventional, siloed approach to medicine. We had treated his high blood pressure as an isolated plumbing problem in his cardiovascular system, completely disconnected from the intricate metabolic processes that govern his weight, energy, and overall health. This separation is where standard care can inadvertently set patients up for failure. The prime suspects in this frustrating trade-off are often the older, non-vasodilating beta-blockers, a class of drugs that includes some of the most commonly prescribed medications like atenolol, metoprolol, and propranolol.¹

For decades, these have been go-to drugs for hypertension. They work, and they work well, by blocking the effects of adrenaline, which slows the heart rate and reduces the force of its contractions. The problem is, this action has unintended metabolic consequences. A significant body of research confirms what David experienced firsthand: these specific medications are consistently linked to a modest but clinically meaningful weight gain, often in the range of 1.2 to 3.4 kilograms (about 2.5 to 7.5 pounds), particularly in the first few months of therapy.²

This isn’t a matter of a patient suddenly losing willpower. These drugs can actively sabotage the body’s metabolic machinery in two critical ways. First, they slow the body’s engine. Research suggests that beta-blockers can reduce the basal metabolic rate—the number of calories your body burns at rest—and blunt the thermogenic response to meals, meaning you burn fewer calories from the food you eat.² Second, they can directly undermine a patient’s ability to fight back. A common side effect is fatigue and diminished exercise tolerance, making it physically harder for patients to engage in the very activity that is crucial for managing both weight and blood pressure.² For a patient like David, who was trying his best, it was like trying to run a race with the brakes partially engaged.

This led me to a critical realization about the language we use in medicine. The term “beta-blocker” itself is a dangerous oversimplification. While the evidence clearly points to metabolic problems with older drugs like atenolol and metoprolol, it is not a universal truth for the entire class.¹ Newer, vasodilating beta-blockers—such as nebivolol and carvedilol—behave differently. The 2023 European Society of Hypertension (ESH) guidelines, for instance, highlight these specific agents as being suitable for patients with obesity precisely because they appear to lack the negative metabolic effects of their predecessors.⁷

The distinction is profound. The negative effects seem tied to the pure beta-blockade that slows the body’s entire system down. The vasodilating (vessel-widening) properties of the newer agents introduce a counteracting, potentially beneficial, mechanism. A clinician who isn’t aware of this nuance might lump all beta-blockers together, unnecessarily denying a patient a potentially vital medication. A patient with heart failure, for example, might have a clear indication for a beta-blocker, and choosing a metabolically neutral one like carvedilol could be the difference between success and failure. This understanding was my first step away from simply categorizing drugs and toward understanding their true, systemic impact. It was the beginning of my search for a better framework.

Part II: The Epiphany: Discovering the Body’s Metabolic Blueprint

A Lightbulb Moment from an Unlikely Source: Systems Biology

My frustration with the “whack-a-mole” cycle sent me searching for a new way of thinking, far outside the traditional boundaries of my clinical training. I found it in the fascinating field of Systems Biology. The concept was both simple and revolutionary, and it changed the way I view human health forever.

I began to think of it through an analogy: The Metabolic Blueprint. For years, I had been practicing medicine like a mechanic who views a car as a collection of separate parts. If the tire is flat, you patch the tire. If the engine overheats, you fix the radiator. If the radio is broken, you replace the radio. Each problem is addressed in isolation. But this approach misses the most critical element: the car’s integrated operating system—the complex network of wiring, sensors, and computer code that connects and controls everything. A persistent engine warning light might not be a problem with the engine itself, but a bug in the software or a faulty sensor feeding it bad information. Fixing the “part” without understanding the “system” is a recipe for recurring problems.

Systems Biology proposes that the human body works the same way.⁸ It’s not just a collection of organs; it’s an incredibly complex, interconnected system governed by a “Metabolic Blueprint.” This blueprint is our body’s operating system, a vast network of genes, hormones, and signaling pathways that regulate how we produce, use, and store energy.⁸ From this new perspective, conditions like high blood pressure and weight gain were no longer just faulty parts. They were error messages—symptoms generated by a deeper glitch in the underlying metabolic code.

Decoding Metabolic Syndrome: The Real Culprit

Armed with this new analogy, I looked at David’s case again, and everything clicked into place. His high blood pressure and his frustrating weight gain were not two separate diseases. They were two of the most visible symptoms of a single, underlying systemic dysfunction: Metabolic Syndrome.¹¹

Metabolic Syndrome is not a disease in the traditional sense but a cluster of five specific risk factors that, when they occur together, dramatically increase the risk for heart disease, stroke, and diabetes. The diagnosis is made when a person has three or more of the following ¹³:

1. Central Obesity: Excess fat carried around the waist, creating an “apple shape.” This is defined as a waist circumference greater than 40 inches (102 cm) for men or 35 inches (89 cm) for women, though these numbers can vary by ethnicity.
2. High Blood Pressure (Hypertension): A reading of 130/80 mm Hg or higher, or being on medication for hypertension.
3. High Triglycerides: A level of these blood fats at or above 150 mg/dL.
4. Low HDL (“Good”) Cholesterol: A level below 40 mg/dL for men or 50 mg/dL for women.
5. High Fasting Blood Sugar: A level of 100 mg/dL or higher, indicating the body is struggling to manage glucose.

The true epiphany, the key that unlocked the entire puzzle, was understanding the central mechanism that connects all these dots. The master bug in the metabolic code, the hub of this dysfunctional wheel, is a condition called insulin resistance.¹² Insulin is the hormone that acts like a key, allowing sugar (glucose) from our blood to enter our cells to be used for energy. In insulin resistance, the cells’ locks become “rusty.” They don’t respond properly to insulin’s signal. The body’s response is to pump out more and more insulin to try to force the glucose into the cells, a state known as hyperinsulinemia.¹²

This state of high insulin is the linchpin. It directly causes the kidneys to retain more sodium and water, which raises blood pressure. It alters how the liver processes fats, leading to the production of more triglycerides and less of the protective HDL cholesterol. And over time, as the pancreas struggles to keep up with the demand for more insulin, blood sugar levels begin to rise, leading first to pre-diabetes and then to full-blown type 2 diabetes. The excess abdominal fat itself is a key driver of this whole process, releasing inflammatory substances that worsen insulin resistance.¹⁵

This chain of events led to the most profound shift in my clinical perspective. For many, if not most, patients like David, hypertension and obesity are not the root diseases. They are downstream consequences, the visible symptoms of this deeper metabolic dysregulation. This understanding revealed the absurdity of our initial approach. We had treated David’s high blood pressure—a symptom of insulin resistance—with a medication (an older beta-blocker) known to worsen insulin resistance and metabolic health.² It was the clinical equivalent of trying to fix a software bug by pouring water on the overheating computer. You might cool it down for a moment, but you are fundamentally damaging the motherboard in the process.

It became clear that the “best” blood pressure medication wasn’t simply the one that lowered a number on a cuff most effectively. The best medication had to be one that worked in harmony with the body’s Metabolic Blueprint—one that, at the very least, did no further harm, and ideally, helped to repair the underlying glitch.

Part III: A Strategist’s Guide to Antihypertensives: Rewriting the Blueprint

This new, systems-level understanding demanded a complete re-evaluation of the tools in my toolbox. Instead of thinking about medications by their traditional class, I began to categorize them based on their true impact on a patient’s Metabolic Blueprint. I sorted them into three distinct categories: those that disrupt the system, those that are neutral, and those that actively help enhance it.

1. System Disruptors: Drugs That Smudge the Blueprint

This category includes medications that, while effective at lowering blood pressure, carry a significant risk of disrupting a patient’s metabolic health, potentially making the underlying problem of Metabolic Syndrome worse.

• Revisiting Beta-Blockers: The primary examples are the older, non-vasodilating beta-blockers like atenolol and metoprolol. In the language of our blueprint analogy, these drugs are like a command that slows down the entire operating system. By reducing metabolic rate and promoting insulin resistance, they directly “smudge” the blueprint, making it harder for the body to regulate energy and weight effectively.² For a patient already struggling with metabolic issues, this can be a significant step in the wrong direction.
• The Diuretic Nuance: High-dose thiazide and thiazide-like diuretics (e.g., hydrochlorothiazide, chlorthalidone) also fall into this category, albeit with more nuance. They are cornerstones of hypertension management and are highly effective. However, particularly at higher doses, they can have unfavorable effects on glucose metabolism and lipid profiles, potentially increasing insulin resistance and the risk of developing new-onset diabetes.⁷ While often necessary, especially in combination therapy, their potential to smudge the blueprint must be acknowledged and managed, often by using the lowest effective dose or combining them with a metabolically favorable drug.

2. System Neutrals: The Safe but Passive Options

These are the workhorses of hypertension management. They effectively lower blood pressure without causing significant harm to the underlying metabolic system. They are “safe” from a metabolic perspective, but they are also passive—they don’t actively help repair the glitches in the blueprint.

• Calcium Channel Blockers (CCBs): Drugs like amlodipine and diltiazem are generally considered weight-neutral.¹ Their primary mechanism is to relax blood vessels by blocking the entry of calcium into muscle cells, an action that is largely independent of the core metabolic pathways governing insulin and glucose.¹⁷ While some fluid retention (edema) can occur, this is distinct from true fat gain.²
• Alpha-Blockers: Medications such as prazosin are also considered to have little to no effect on weight.¹ They work by blocking norepinephrine from tightening blood vessels, another mechanism that sidesteps direct interference with metabolism.²⁴
• The “Water Pill” Clarification and the Communication Gap: This category is also the proper place to clarify the effect of diuretics on weight. When a patient starts a diuretic, or “water pill,” they often see a rapid drop on the scale. This can create a powerful, but misleading, sense of success. It is crucial to understand that this initial loss is almost entirely water weight, not body fat.²⁵ These drugs work by telling the kidneys to excrete more sodium and water, which reduces the fluid volume in the blood vessels and lowers blood pressure.²⁵

This distinction between water weight and fat loss is more than a technicality; it represents a critical communication point between doctor and patient. I learned this the hard way. A patient sees the scale drop by three or four pounds in the first week and feels elated. They believe their diet and exercise efforts are finally paying off. Then, as their body naturally rehydrates, that weight comes right back. The patient feels defeated, concluding that their efforts have failed or the medication has stopped working. This cycle of hope and disappointment can severely undermine trust and long-term adherence to a treatment plan.²⁶ The problem isn’t the drug itself, which may be essential for managing fluid overload or blood pressure, but the misunderstanding of its effect. A core part of my journey toward becoming a systems-focused strategist was realizing that educating my patients—explaining

how a drug works and what to expect—is as vital as writing the prescription itself.

3. System Enhancers: The True Therapeutic Allies

This is the category that represents the paradigm shift. These are medications that do more than just lower blood pressure; they work in synergy with the Metabolic Blueprint, actively helping to repair the underlying dysfunctions of Metabolic Syndrome. For patients like David, these drugs are true therapeutic allies.

• Angiotensin-Converting Enzyme (ACE) Inhibitors: This class, which includes common drugs like lisinopril, enalapril, and ramipril, is a cornerstone of this new approach. Decades of research show they are not only weight-neutral but may even be slightly favorable for weight management.¹ More profoundly, they have direct, positive effects on the blueprint itself. Multiple large clinical trials have demonstrated that ACE inhibitors improve the body’s sensitivity to insulin and can significantly reduce the risk of a patient developing new-onset type 2 diabetes.¹⁷ They also have beneficial effects on lipid profiles, particularly by helping to lower triglycerides.¹⁸ They are not just treating a symptom; they are intervening in the core pathology.
• Angiotensin II Receptor Blockers (ARBs): This class, including drugs like losartan, valsartan, and candesartan, offers similar, powerful benefits. Like ACE inhibitors, they block the renin-angiotensin-aldosterone system (RAAS), a key hormonal cascade that drives hypertension and is deeply intertwined with metabolic health.²⁹ They are also considered metabolically favorable, with neutral or positive effects on weight and insulin sensitivity.¹⁷
• The Telmisartan Superpower: Within the ARB class, one drug stands out as a remarkable example of a “System Enhancer”: telmisartan. Research has uncovered a unique dual mechanism of action for this medication. In addition to its primary job of blocking the angiotensin II receptor, telmisartan also activates a specific cellular receptor called PPAR-δ (peroxisome proliferator-activated receptor delta).³² Activating this pathway has been shown to have stunning metabolic benefits, including preventing high-fat diet-induced obesity and specifically reducing visceral fat—the most dangerous type of fat that drives insulin resistance. Remarkably, these effects occur without changing food intake, suggesting a direct reprogramming of the body’s energy metabolism.³² Telmisartan is the ultimate example of a drug that fixes multiple bugs in the metabolic code simultaneously.

The clear advantage of ACE inhibitors and ARBs for patients with metabolic concerns is not simply about avoiding weight gain. It’s about actively intervening in the pathophysiology of Metabolic Syndrome. By targeting the RAAS, these drugs are working on a root cause, not just a peripheral symptom.¹⁷ For any patient presenting with the dual challenge of high blood pressure and excess weight—a clinical picture that screams Metabolic Syndrome—these “System Enhancers” represent the most logical and strategic first-line therapeutic choice.

To synthesize this information, the following tables provide a clear, comparative overview for navigating these choices.

Table 1: The Antihypertensive Spectrum: A Metabolic Impact Scorecard

Drug Class	Examples	Blood Pressure Efficacy	Impact on Weight	Impact on Insulin/Glucose	Impact on Lipids	Overall “Blueprint” Rating
Non-vasodilating Beta-Blockers	Atenolol, Metoprolol	High	Gain 1	Negative (Increases insulin resistance) 4	Negative	Disruptor
Vasodilating Beta-Blockers	Carvedilol, Nebivolol	High	Neutral 7	Neutral 7	Neutral	Neutral
Thiazide Diuretics	Hydrochlorothiazide, Chlorthalidone	High	Neutral (water loss, not fat loss) 25	Negative (at high doses) 17	Negative (at high doses)	Neutral to Disruptor
Calcium Channel Blockers (CCBs)	Amlodipine, Diltiazem	High	Neutral 19	Neutral 17	Neutral	Neutral
ACE Inhibitors	Lisinopril, Enalapril	High	Neutral to slight loss 18	Positive (Improves insulin sensitivity) 17	Positive	Enhancer
Angiotensin Receptor Blockers (ARBs)	Losartan, Telmisartan	High	Neutral to slight loss 32	Positive (Improves insulin sensitivity) 17	Positive	Enhancer

Table 2: A Practical Guide to System-Enhancing Medications

Drug Class	Common Generic Names	Key Metabolic Advantage	Important Considerations
ACE Inhibitors	Lisinopril, Ramipril, Enalapril, Benazepril	Improves insulin sensitivity, lowers risk of new-onset diabetes, favorable lipid effects.17	A dry, persistent cough is a common side effect for some individuals. Should be used with caution in patients with kidney issues.28
Angiotensin Receptor Blockers (ARBs)	Losartan, Valsartan, Candesartan, Irbesartan, Olmesartan	Similar metabolic benefits to ACE inhibitors but without the cough side effect.17	Generally very well tolerated. As with ACE inhibitors, kidney function should be monitored.29
	Telmisartan	Unique dual action: In addition to standard ARB benefits, it activates PPAR-δ, which may help reduce visceral fat and prevent diet-induced obesity.32	An excellent strategic choice for patients with significant features of Metabolic Syndrome.

Part IV: Building a Resilient System: The Ultimate Strategy for Health

Medication is a Tool, Not the Entire Toolbox

Choosing a “System Enhancer” like an ACE inhibitor or an ARB is a powerful strategic move. It aligns the pharmacological treatment with the goal of improving overall metabolic health. But my journey into systems thinking taught me a final, crucial lesson: even the most advanced medication is only a patch for a faulty system. It can help manage the error messages and even repair some of the code, but it cannot, by itself, build a fundamentally new, resilient operating system. The ultimate goal must be to repair and strengthen the entire Metabolic Blueprint through foundational lifestyle changes.

This integrated approach is especially critical because, in many ways, official clinical guidelines are still catching up to this systems-level view. Multiple analyses point out that there are still no specific, dedicated guidelines for the management of obesity-related hypertension.⁷ The 2023 ESH guidelines represent a significant step forward by acknowledging the metabolic differences among drug classes, but the lack of a unified, global consensus leaves many clinicians and patients navigating this complex territory without a clear map.⁷ This “guideline gap” validates the confusion that patients like David feel and underscores the urgent need for a proactive, integrated strategy that patients and doctors can build together.

The Foundational Pillars of Metabolic Health

The true path to reversing Metabolic Syndrome and achieving lasting health is built on a foundation of non-pharmacological interventions. These are not just “healthy habits”; they are targeted strategies designed to directly repair the glitches in the Metabolic Blueprint.

• 1. Strategic Weight Loss: This is the single most powerful intervention. Blood pressure often rises in direct proportion to weight gain.³⁵ Losing even a modest amount of weight—as little as 5% to 10% of total body weight—can produce dramatic improvements, lowering blood pressure by 5-20 mmHg and positively impacting every single component of Metabolic Syndrome.⁷ The focus should be less on the number on the scale and more on waist circumference, as reducing the visceral fat stored around the abdomen is key to reversing insulin resistance.¹⁶
• 2. Targeted Nutrition: This is not about deprivation; it’s about adopting a nutritional strategy specifically aimed at improving metabolic function. Eating plans like the Dietary Approaches to Stop Hypertension (DASH) diet and the Mediterranean diet, which are rich in whole grains, fruits, vegetables, and lean proteins, have been proven to lower blood pressure by as much as 11 mmHg.³⁵ Two key tactics are essential:

• Reduce Sodium, Increase Potassium: Most sodium in the modern diet comes from processed foods. Limiting sodium to less than 2,300 mg (and ideally 1,500 mg) per day can lower blood pressure by 5-6 mmHg. Simultaneously, increasing potassium intake from foods like leafy greens, tomatoes, bananas, and avocados helps the body excrete sodium and eases pressure on blood vessels.³⁵
• Prioritize Whole Foods: Shifting away from processed foods and toward fresh, whole ingredients is a simple rule with profound effects. It naturally lowers sodium and sugar intake while increasing fiber, potassium, and other vital nutrients.³⁷

• 3. Regular Physical Activity: Exercise is non-negotiable medicine. Aiming for at least 150 minutes of moderate-intensity aerobic activity (like brisk walking, cycling, or swimming) per week can lower blood pressure by 5-8 mmHg.³⁵ More importantly, physical activity makes the body’s cells more sensitive to insulin, directly combating the central hub of Metabolic Syndrome. It builds muscle, which acts like a sponge to soak up excess blood sugar.³⁷
• 4. Limit Alcohol: While moderate alcohol consumption may have some cardiovascular benefits, excessive intake can significantly raise blood pressure and, critically, can make blood pressure medications less effective.³⁵ Limiting intake to one drink per day for women and two for men is a prudent part of a comprehensive management plan.

Part V: Conclusion: From Frustration to Freedom

I often think back to David. His journey became my journey. After our shared frustration with the “whack-a-mole” approach, we changed course. We switched his medication from a “System Disruptor” to a “System Enhancer”—an ARB that wouldn’t fight against his metabolic goals. But more importantly, we stopped talking about his blood pressure and his weight as two separate problems. We started talking about his “Metabolic Blueprint.” We focused on the foundational pillars: a whole-foods-based diet, consistent daily walks, and strategic weight loss measured by his belt notches, not just the scale.

The transformation was slow but steady. Over the next year, his blood pressure remained perfectly controlled, but this time, the number on the scale moved in the right direction. He broke the vicious cycle. He was no longer just a patient with hypertension; he was the successful manager of his own complex, integrated system.

His success solidified my own transformation—from a clinician who chased symptoms to a health strategist who seeks to understand and repair underlying systems. The frustration I once felt has been replaced by a sense of profound optimism. We have the knowledge and the tools to move beyond the simplistic, siloed model of care.

This report is the culmination of that journey. It is a new blueprint for understanding the intricate dance between blood pressure, weight, and metabolism. My hope is that it empowers you to see yourself not as a collection of isolated problems to be fixed, but as the CEO of your own health. You are in charge of a complex, interconnected, and ultimately resilient system. The path to lasting well-being lies in partnering with your healthcare provider to co-create a personalized, integrated strategy—one that chooses the right tools and builds a strong foundation. It is a path that leads away from the frustration of whack-a-mole and toward the freedom of true, sustainable health.

Works cited

1. Can Blood Pressure Medications Cause Weight Gain? – Healthline, accessed on August 8, 2025, https://www.healthline.com/health/high-blood-pressure/can-blood-pressure-medications-cause-weight-gain
2. Antihypertensive Medications and Weight Gain – PMC, accessed on August 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8109551/
3. Do Beta Blockers Cause Weight Gain – Consensus Academic Search Engine, accessed on August 8, 2025, https://consensus.app/questions/do-beta-blockers-cause-weight-gain/
4. Does Blood Pressure Medication Cause Weight Gain – Consensus Academic Search Engine, accessed on August 8, 2025, https://consensus.app/questions/does-blood-pressure-medication-cause-weight-gain/
5. Beta blockers: Do they cause weight gain? – Mayo Clinic, accessed on August 8, 2025, https://www.mayoclinic.org/diseases-conditions/high-blood-pressure/expert-answers/beta-blockers/faq-20058385
6. pmc.ncbi.nlm.nih.gov, accessed on August 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8109551/#:~:text=There%20are%20multiple%20proposed%20mechanisms,metabolism%20and%20decreased%20physical%20activity.
7. Mechanisms and treatment of obesity-related hypertension—Part 2 …, accessed on August 8, 2025, https://academic.oup.com/ckj/article/18/3/sfaf035/8009105
8. Metabolic syndrome: from epidemiology to systems biology – PMC, accessed on August 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2829312/
9. Genetics and Systems Biology of the Metabolic Syndrome | LUMC, accessed on August 8, 2025, https://www.lumc.nl/en/afdelingen/human-genetics/genetics-and-systems-biology-of-the-metabolic-syndrome/
10. Systems Biology: A Multi-Omics Integration Approach to Metabolism and the Microbiome, accessed on August 8, 2025, https://e-enm.org/journal/view.php?number=2069
11. What is Metabolic Syndrome? – American Heart Association, accessed on August 8, 2025, https://www.heart.org/en/health-topics/metabolic-syndrome/about-metabolic-syndrome
12. Metabolic Syndrome | Johns Hopkins Medicine, accessed on August 8, 2025, https://www.hopkinsmedicine.org/health/conditions-and-diseases/metabolic-syndrome
13. Metabolic syndrome | Better Health Channel, accessed on August 8, 2025, https://www.betterhealth.vic.gov.au/health/conditionsandtreatments/metabolic-syndrome
14. Metabolic syndrome – Symptoms & causes – Mayo Clinic, accessed on August 8, 2025, https://www.mayoclinic.org/diseases-conditions/metabolic-syndrome/symptoms-causes/syc-20351916
15. Metabolic Syndrome: What It Is, Causes, Symptoms & Treatment – Cleveland Clinic, accessed on August 8, 2025, https://my.clevelandclinic.org/health/diseases/10783-metabolic-syndrome
16. Hypertension and Obesity – Endocrine Society, accessed on August 8, 2025, https://www.endocrine.org/~/media/endosociety/files/ep/rphr/59/rphr_vol_59_ch_09_hypertension_and_obesity.pdf
17. Antihypertensive drugs and glucose metabolism – PMC, accessed on August 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4110601/
18. Effects of ACE Inhibitors on Insulin Resistance and Lipid Profile in …, accessed on August 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3814531/
19. www.healthline.com, accessed on August 8, 2025, https://www.healthline.com/health/heart-health/heart-medications-that-cause-weight-gain#:~:text=Calcium%20channel%20blockers%20used%20to,have%20no%20effect%20on%20weight.
20. Does verapamil (calcium channel blocker) cause weight gain? – Dr.Oracle AI, accessed on August 8, 2025, https://www.droracle.ai/articles/202363/does-verapamil-cause-weight-gain
21. Vasodilators: Types and Side Effects – Cleveland Clinic, accessed on August 8, 2025, https://my.clevelandclinic.org/health/drugs/23207-vasodilators
22. Common medications that cause weight gain – MDLinx, accessed on August 8, 2025, https://www.mdlinx.com/article/common-medications-that-cause-weight-gain/10ELKj7VLNRiEiOL0g0OZS
23. pmc.ncbi.nlm.nih.gov, accessed on August 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6109660/#:~:text=For%20alpha%2Dblockers%2C%20weight%20gain,a%20commonly%20reported%20side%20effect.
24. Alpha blockers – Mayo Clinic, accessed on August 8, 2025, https://www.mayoclinic.org/diseases-conditions/high-blood-pressure/in-depth/alpha-blockers/art-20044214
25. Do diuretics help you lose weight? | Optum Perks, accessed on August 8, 2025, https://perks.optum.com/blog/diuretics-weight-loss
26. The Truth About Water Pills For Weight Loss – HealthMatch, accessed on August 8, 2025, https://healthmatch.io/weight-management/water-pills
27. Should You Take Diuretics for Weight Loss? Here’s What Dietitians Say – EatingWell, accessed on August 8, 2025, https://www.eatingwell.com/should-you-take-diuretics-for-weight-loss-8424100
28. Does lisinopril (angiotensin-converting enzyme inhibitor) cause weight gain as a side effect?, accessed on August 8, 2025, https://www.droracle.ai/articles/31830/does-lisinopril-have-weight-gain-among-side-effects
29. Candesartan (oral route) – Side effects & dosage – Mayo Clinic, accessed on August 8, 2025, https://www.mayoclinic.org/drugs-supplements/candesartan-oral-route/description/drg-20068192
30. Angiotensin receptor blockers (ARBs) – Heart Matters magazine – BHF, accessed on August 8, 2025, https://www.bhf.org.uk/informationsupport/heart-matters-magazine/medical/drug-cabinet/arbs
31. Renin Inhibitors – CV Pharmacology, accessed on August 8, 2025, https://cvpharmacology.com/vasodilator/renin
32. Telmisartan Prevents Weight Gain and Obesity Through Activation of …, accessed on August 8, 2025, https://www.ahajournals.org/doi/10.1161/hypertensionaha.109.143958
33. Inhibition of the Renin-Angiotensin System Reduces Gene Expression of Inflammatory Mediators in Adipose Tissue Independent of Energy Balance – Frontiers, accessed on August 8, 2025, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.682726/full
34. Therapeutic Considerations in the Treatment of Obesity Hypertension – PubMed Central, accessed on August 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8101864/
35. 10 ways to control high blood pressure without medication – Mayo Clinic, accessed on August 8, 2025, https://www.mayoclinic.org/diseases-conditions/high-blood-pressure/in-depth/high-blood-pressure/art-20046974
36. Blood pressure medication: Still necessary if I lose weight? – Mayo Clinic, accessed on August 8, 2025, https://www.mayoclinic.org/diseases-conditions/high-blood-pressure/expert-answers/blood-pressure-medication/faq-20058056
37. 15 natural ways to lower your blood pressure – Medical News Today, accessed on August 8, 2025, https://www.medicalnewstoday.com/articles/318716
38. High Blood Pressure (Hypertension) (Holistic) – Health Information Library | PeaceHealth, accessed on August 8, 2025, https://www.peacehealth.org/medical-topics/id/hn-1033009